Scancell, the developer of novel immunotherapies for the treatment of cancer, is pleased to announce that it has signed a collaboration and non-exclusive research agreement with a US-based, clinical stage antibody company to assess monoclonal antibodies (mAbs) targeting tumour-associated glycans … Continued
3.01.20 It was the year of Brexit (again), another bruising general election, and trauma in the retail fund industry with the demise of Woodford and the gating of property funds. Against this backdrop the VCT and EIS industry continued to … Continued
Oxford BioTherapeutics Ltd. (“OBT”), a clinical stage oncology company developing antibody-based immuno-oncology therapies, has announced the initiation of the dose-escalation portion of its U.S. Phase I program for OBT076, a CD205 targeting antibody-drug conjugate (ADC), in patients with advanced solid … Continued
Calculus Capital has sold their investment in London-based marketing agency Once Upon a Time (OUAT) in a deal that netted investors an expected total return of 1.8x, excluding the tax benefits associated with investing through EIS. OUAT is a marketing … Continued
